ArticleInternational journal of clinical and experimental pathology2018
Prognostic value of transducer of ErbB2.1 (TOB1) expression in patients with gastric cancer: tissue microarray analysis.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransducer of ErbB2.1 (TOB1) protein plays an important role in cell cycle regulation, apoptosis induction, and metastasis inhibition. However, the prognostic value of TOB1 in the survival of gastric cancer (GC) patients has not been examined.
methodsIn the present study, western blot and real-time qPCR were used to detect the protein and mRNA level of TOB1 in fresh samples from GC patients. A tissue microarray comprising 90 pairs of primary GC and adjacent normal tissues was analysed using immunohistochemistry. Western blot analysis of 16 samples from GC patients showed that 81% (13/16) of patients exhibited decreased expression of TOB1, and real-time qPCR analysis showed that GC patients had decreased expression of TOB1 mRNA.
resultsTissue microarrays showed that 72.2% of gastric cancer tissues exhibited down-regulated expression of TOB1, and the expression level was significantly lower in cases with poor differentiation and positive lymph node metastasis, compared with normal tissues. Moreover, the Kaplan-Meier analysis indicated that patients with low TOB1 expression had shorter survival time than those with high TOB1 expression (5-year survival rate, 26.2% vs. 56.0%, P=0.002). In addition, multivariate analysis indicated that TOB1 was an independent prognostic factor for outcome in gastric cancer (HR, 0.256; 95% CI, 0.127-0.514; P=0.000).
conclusionsDown-regulated TOB1 expression was found in gastric cancer. Furthermore, low TOB1 expression may be an independent indicator of poor prognosis in gastric cancer.
Indexed as
Identifiers
31949796PMC6962808W3027157295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.